Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. (Q53258665)

12 May 2018

title

Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. (English)

1 reference

12 May 2018

1 reference

2

1 reference

12 May 2018

author name string

Estefanía Carrasco-García

1

1 reference

12 May 2018

Silvina Grasso

3

1 reference

12 May 2018

Lourdes Rocamora-Reverte

4

1 reference

12 May 2018

Mariano Conde

5

1 reference

12 May 2018

Angeles Gómez-Martínez

6

1 reference

12 May 2018

Pilar García-Morales

7

1 reference

12 May 2018

José A Ferragut

8

1 reference

12 May 2018

Isabel Martínez-Lacaci

9

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 April 2011

1 reference

12 May 2018

Experimental Cell Research

published in

1 reference

12 May 2018

volume

317

1 reference

12 May 2018

issue

10

1 reference

12 May 2018

page(s)

1476-1489

1 reference

12 May 2018

Changing paradigms--an update on the multidisciplinary management of malignant glioma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

An integrated genomic analysis of human glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Specificity within the EGF family/ErbB receptor family signaling network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cell signaling by receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Secondary dimerization between members of the epidermal growth factor receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

CDK inhibitors: positive and negative regulators of G1-phase progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cell cycle. Order from destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Characterization of a novel epidermal-growth-factor-receptor-related 200-kDa tyrosine kinase in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGF mutant receptor vIII as a molecular target in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The EGFRvIII variant in glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor targeting in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Evolutionary analysis of the ErbB receptor and ligand families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The EGF receptor family: spearheading a merger of signaling and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

c-erbB-4/HER4: friend or foe?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Nuclear EGFR contributes to acquired resistance to cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Designer therapies for glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.015

10.1016/J.YEXCR.2011.03.015

7 January 2021

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

21439954

1 reference

12 May 2018